Market capitalization | €5.96b |
Enterprise Value | €6.03b |
P/E (TTM) P/E ratio | 17.97 |
EV/FCF (TTM) EV/FCF | 31.24 |
EV/Sales (TTM) EV/Sales | 4.22 |
P/S ratio (TTM) P/S ratio | 4.17 |
P/B ratio (TTM) P/B ratio | 6.45 |
Dividend yield | 3.82% |
Last dividend (FY24) | €1.62 |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
7 Analysts have issued a Orion forecast:
7 Analysts have issued a Orion forecast:
Sep '24 |
+/-
%
|
||
Revenue | 1,429 1,429 |
23%
23%
|
|
Gross Profit | 856 856 |
34%
34%
|
|
EBITDA | 426 426 |
60%
60%
|
EBIT (Operating Income) EBIT | 374 374 |
74%
74%
|
Net Profit | 332 332 |
91%
91%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. It specializes in central nervous system disorders, oncology, and respiratory diseases. The firm's customers are specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories. The company was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.
Head office | Finland |
CEO | Aino Hurme |
Employees | 3,632 |
Founded | 1917 |
Website | www.orion.fi |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.